Overview

AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients

Status:
Completed

Trial end date:
2014-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate safety of apixaban in Japanese acute DVT/PE subjects when symptomatic DVT/PE subjects are treated with 10 mg BID apixaban for 7 days as initial therapy followed by 5 mg BID apixaban for 23 weeks as long-term therapy (total treatment period is 24 weeks)

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Collaborator:

Bristol-Myers Squibb

Treatments:

Apixaban
Calcium heparin
Heparin
Warfarin